Research programme: eukaryotic initiation factor 5A-1 modulators - Eloxx Pharmaceuticals

Drug Profile

Research programme: eukaryotic initiation factor 5A-1 modulators - Eloxx Pharmaceuticals

Alternative Names: F5A1 modulators; Factor 5A1 modulators

Latest Information Update: 04 Jan 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Senesco Technologies
  • Developer Senesco Technologies; Sevion Therapeutics
  • Class
  • Mechanism of Action Apoptosis inhibitors; Eukaryotic initiation factor 5A modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Autoimmune disorders; Cancer; Glaucoma; HIV infections; Inflammatory bowel diseases; Ischaemic heart disorders; Septic shock; Type 1 diabetes mellitus

Most Recent Events

  • 17 Nov 2014 No development reported - Preclinical for Autoimmune disorders in USA (unspecified route)
  • 17 Nov 2014 No development reported - Preclinical for Cancer in USA (unspecified route)
  • 17 Nov 2014 No development reported - Preclinical for Inflammatory bowel disease in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top